OBJECTIVE -Pharmacological profiles of biphasic insulin aspart 30/70 (BIAsp 30) once daily (OD), twice daily (b.i.d.), and three times daily (t.i.d.) were compared with other insulin regimens in two crossover glucose clamp studies of insulin-treated type 2 diabetic patients. P remixed insulin analogs are a commonly prescribed first insulin therapy for type 2 diabetic patients and may be a simpler alternative to basalbolus therapy (1,2). Compared with biphasic human insulin 30/70 (BHI 30), the modern premixed insulin analog, biphasic insulin aspart 30/70 (BIAsp 30) has pharmacokinetics (PK) that more closely match endogenous insulin secretion (3,4). Therefore, an initial once-daily (OD) BIAsp 30 regimen can be safely intensified to twice-daily (b.i.d.) or threetimes-daily (t.i.d.) injections (5). To compare the PK and pharmacodynamic (PD) profiles of these different regimens, two crossover glucose clamp studies were carried out in insulin-treated patients with type 2 diabetes. 
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remixed insulin analogs are a commonly prescribed first insulin therapy for type 2 diabetic patients and may be a simpler alternative to basalbolus therapy (1, 2) . Compared with biphasic human insulin 30/70 (BHI 30), the modern premixed insulin analog, biphasic insulin aspart 30/70 (BIAsp 30) has pharmacokinetics (PK) that more closely match endogenous insulin secretion (3, 4) . Therefore, an initial once-daily (OD) BIAsp 30 regimen can be safely intensified to twice-daily (b.i.d.) or threetimes-daily (t.i.d.) injections (5) . To compare the PK and pharmacodynamic (PD) profiles of these different regimens, two crossover glucose clamp studies were carried out in insulin-treated patients with type 2 diabetes. The glucose clamp procedure was similar for both studies: at each dosing visit, patients underwent a 24-h euglycemic glucose clamp using a glucosecontrolled insulin infusion system (Biostator; MTB Medizintechnik, Germany) while fasting. Blood glucose was clamped at 5.0 mmol/l by adjusting the intravenous glucose infusion. Blood sam-ples were taken from subjects before test insulin dosing and during the glucose clamps for PK serum insulin measurements. The Biostator recorded PD glucose infusion rates (GIRs) during the clamps. Statistics. Regimens were compared using 24-h plots of serum insulin (not shown for study 2) and GIR. Area under the curve (AUC) measurements were taken from insulin concentration time plots and GIR time plots using the trapezoidal rule. Due to the different insulin doses used, statistical analyses were performed only on data from BIAsp 30 OD and BHI 30 OD (study 1, both 0.6 units/kg).
RESEARCH DESIGN AND METHODS
RESULTS -One participant withdrew from each study, leaving 23 completers in each. Study 1. The 24-h serum insulin and GIR profiles of BHI 30 OD and BIAsp 30 OD, b.i.d., and t.i.d. showed marked differences ( Fig. 1A and B CONCLUSIONS -The PK and PD profiles of BHI 30 and BIAsp 30 OD, b.i.d., and t.i.d. were well characterized. BIAsp 30 OD had pharmacological advantages over BHI 30 OD (earlier and higher serum insulin levels), which may confer greater postprandial glycemic control (3,6 -8) . During the 24-h clamp, serum insulin following BIAsp 30 OD and BHI 30 OD returned to similar levels, suggesting that the duration of action of protaminated aspart is similar to that of NPH insulin (3, 4) . BIAsp 30 t.i.d. gave a similar PD profile to that of basal-bolus therapy with insulin glargine/glulisine and demonstrated slightly greater overall metabolic effect at the same total dose, possibly due to the higher GIR following the third daily injection. This greater glucose-lowering effect with BIAsp 30 during the evening/ nighttime may pose an increased risk of nocturnal hypoglycemia, so careful titration of the evening injection is needed. If these pharmacological results can be confirmed in a clinical trial, BIAsp 30 t.i.d. may represent an alternative to basalbolus therapy requiring at least one fewer daily injection. 
